Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer
NEJM Evidence · 26.05.2026 · 5 (6)
DOI: 10.1056/evidoa2500202 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift NEJM Evidence, erschienen am 26.05.2026. Verfasst von Mark Clemons und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON. Hauptthemen laut MEDLINE: Breast Neoplasms, Diphosphonates, Imidazoles, Bone Density Conservation Agents. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON.
- Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON.
- Escarpment Cancer Research Institute and McMaster University, Hamilton, ON, Canada.
- William Osler Cancer Centre, Brampton, ON, Canada.
- Stronach Regional Cancer Center, Newmarket, ON, Canada.
- Department of Oncology, Cancer Centre of Southeastern Ontario and Queen's University, Kingston, ON, Canada.
Zitieren
APA
Clemons, M., Stober, C., Pond, G. R., Conter, H., Simos, D., Dhesy-Thind, S., Mates, M., Trinkaus, M., Hilton, J., Savard, M. F., Fergusson, D., Vandermeer, L., & Awan, A. A. (2026). Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer. NEJM Evidence, 5(6). https://doi.org/10.1056/evidoa2500202
Vancouver
Clemons M, Stober C, Pond GR, Conter H, Simos D, Dhesy-Thind S, et al. Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer. NEJM Evidence. 2026;5(6). doi:10.1056/evidoa2500202
BibTeX
@article{Clemons2026,
author = {Clemons, Mark and Stober, Carol and Pond, Gregory R and Conter, Henry and Simos, Demetrios and Dhesy-Thind, Sukhbinder and Mates, Mihaela and Trinkaus, Mateya and Hilton, John and Savard, Marie-France and Fergusson, Dean and Vandermeer, Lisa and Awan, Arif Ali},
title = {Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer},
journal = {NEJM Evidence},
year = {2026},
volume = {5},
number = {6},
doi = {10.1056/evidoa2500202}
}
EUVIMED